fig2

Non-viral gene therapy for neuromuscular diseases including Duchenne muscular dystrophy using nanovesicles derived from human cells

Figure 2. BioDrone® Platform Technology. (A) A schematic diagram shows the possible mechanism of the high productivity of CDVs compared to EVs (from Lau et al., 2022[106]). (B) Comparison of nanovesicle yield per unit cell between CDVs and EVs in diverse source cells.